What's Next For Illumina?

The DNA sequencing giant dominates its market, but investors are skittish about what the future may hold.

The DNA sequencing giant dominates its market, but investors are skittish about what the future may hold.

For a while, Illumina—the 800-pound gorilla of genomics—could do no wrong. The DNA-sequencing company's market cap more than quadrupled from 2012, to peak at a whopping $34 billion, fueled in part by the growing hype around the potential of genomics to transform how we prevent, diagnose, and treat disease, as well as facilitate medical research discoveries.

Read Full Story